Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | VNN1 | O95497 | 1/20 | 0.30 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2946259 | 0.85 | TDP1 (0.38) | HDAC1 | |
| SCHEMBL8922558 | 0.85 | TDP1 (0.38) | HDAC1 | |
| SCHEMBL3301973 | 0.79 | HDAC3 (0.36) | HSP90AA1CYP1A2HDAC3HDAC1HDAC2 | |
| SCHEMBL11515740 | 0.79 | HSP90AA1 (0.33) | HSP90AA1CYP1A2HDAC3HDAC1HDAC2 | |
| SCHEMBL253297 | 0.78 | — | — | |
| Pyrazine SCHEMBL28089293 | 0.77 | IMPDH2 (0.35) | HSP90AA1CYP1A2HDAC3HDAC1HDAC2 | |
| SCHEMBL27866178 | 0.76 | HRH1 (0.33) | HSP90AA1CYP1A2HDAC3HDAC1HDAC2 | |
| SCHEMBL294804 | 0.76 | — | — | |
| SCHEMBL28362525 | 0.75 | HSP90AA1 (0.40) | HSP90AA1CYP1A2HDAC3HDAC1HDAC2 | |
| SCHEMBL293167 | 0.72 | HSP90AA1 (0.34) | HSP90AA1CYP1A2HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107057830-B | A kind of method of near-infrared pretreatment auxiliary aqueous enzymatic extraction rapeseed oil | 江南大学 | 2019-09-03 | — | — | CN | disclosed |
| CN-107057830-A | A kind of method of near-infrared pretreatment auxiliary aqueous enzymatic extraction rapeseed oil | 江南大学 | 2017-08-18 | — | — | CN | disclosed |
| EP-1713794-B1 | HETEROCYCLE GRAFTED MONOMERS AND RELATED POLYMERS AND HYBRID INORGANIC-ORGANIC POLYMER MEMBRANES | TOYOTA TECHNICAL CT U S A INC (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-1990343-B1 | Azaindoles | AVENTIS PHARMA LTD (GB) | 2012-04-04 | — | — | EP | disclosed |
| US-7943616-B2 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-17 | — | — | US | disclosed |
| EP-2233486-A1 | Azaindoles | Aventis Pharma Limited (GB) | 2010-09-29 | — | — | EP | disclosed |
| EP-1263759-B1 | AZAINDOLES | AVENTIS PHARMA LTD (GB) | 2010-09-08 | — | — | EP | disclosed |
| WO-2010045015-A1 | HETEROARYL SUBSTITUTED THIENO[2,3-D]PYRIMIDINE AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010045012-A1 | HETEROARYL AND PHENYL SUBSTITUTED THIENO [2,3-D] PYRIMIDINES AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010045012-A1 | HETEROARYL AND PHENYL SUBSTITUTED THIENO [2,3-D] PYRIMIDINES AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-22 | — | — | WO | disclosed |
| US-20040198737-A1 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-10-07 | — | — | US | disclosed |
| US-6770643-B2 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-08-03 | — | — | US | disclosed |
| US-20040053931-A1 | Azaindoles | AVENTIS PHARMACEUTICALS INC. | 2004-03-18 | — | — | US | disclosed |
| EP-1397360-A1 | AZAINDOLES | Aventis Pharma Limited (GB) | 2004-03-17 | — | — | EP | disclosed |
| US-20040009983-A1 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-01-15 | — | — | US | disclosed |
| CN-1413213-A | Azaindoles | AVENTIS PHARMA LTD (GB) | 2003-04-23 | — | — | CN | disclosed |
| WO-2003000688-A1 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2003-01-03 | — | — | WO | disclosed |
| EP-1263759-A2 | AZAINDOLES | Aventis Pharma Limited (GB) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001047922-A2 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2001-07-05 | — | — | WO | disclosed |
| US-4638005-A | ELECTRON CARRIERS IN THE PHOTOENZYMATIC PRODUCTION OF HYDROGEN AND AMMONIA | THE COCA-COLA COMPANY | 1987-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198737-A1 | Azaindoles | CCNY, CCNO, CNKSR1 | HSP90AA1 2955/4885CYP1A2 916/4885HDAC3 119/4885 |
| US-20040053931-A1 | Azaindoles | CDKN1A, CDK7, CDK2 | HSP90AA1 3045/4885CYP1A2 131/4885HDAC3 527/4885 |
| US-20040009983-A1 | Azaindoles | CCNY, CCNO, CKS2 | HSP90AA1 3822/4885CYP1A2 621/4885HDAC3 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.